look news india
Amcure Pharma Share Update: A big news is coming out about Emcure Pharmaceuticals Limited, a well-known company in the Indian pharma sector. Veteran global private equity firm Bain Capital has sold its entire remaining stake in the company. Through a block deal on the National Stock Exchange (NSE), Bain Capital has exited the company, completely ending this 12-year-old investment journey. Large domestic and foreign institutional investors (FIIs/DIIs) of the market have bought these shares in large quantities.
Block deal worth ₹352 crore, these giants bought shares of Emcure
According to block deal data received from the stock exchange, Bain Capital has sold 19.4 lakh shares equivalent to about 1 per cent of its stake in Emcure Pharma in the open market. This whole deal on average ₹1,817 per share The total value of which is Rs 352 crore.
Big mutual funds and insurance companies of the country have expressed confidence to buy this stake:
-
HDFC Standard Life Insurance: It made the biggest bet by buying 7.1 lakh shares for ₹130 crore.
-
Axis Mutual Fund (Axis MF): The fund house added shares worth ₹50 crore to its portfolio.
-
Aditya Birla Sun Life MF: He invested ₹47.5 crore and bought 2.6 lakh shares.
Apart from this, reflecting the global investor sentiment, leading institutions like HSBC Mutual Fund, Goldman Sachs, Morgan Stanley and BNP Paribas have also bought shares worth ₹ 25 crore each.
Has a connection with Shark Tank fame Namita Thapar, IPO came in 2024
Emcure Pharma is one of the few pharmaceutical companies in the country whose name is a household name. Popular judge of business reality show ‘Shark Tank India’ Namita Thapar There are whole-time directors in this company. His father Satish Ramanlal Mehta is the founder, CEO and managing director of this company.
If we talk about the company’s stock market journey:
-
The company’s IPO of ₹ 1,952.03 crore came in July 2024.
-
Presently the market capitalization of the company (Market Cap) ₹35,600 crore Has passed beyond.
-
Currently the share price of Emcure Pharma on BSE is ₹1,881.90 Rests at the level of.
According to the shareholding pattern of March 2026, promoters still hold a strong stake of 77.87 percent in the company.
Investors made strong earnings, bumper return of 40% in 1 year
Since its listing in the market, this pharma stock has continuously made investors rich. If we look at the performance of the stock in the recent past, there has been a great rise in it:
-
1 Year Returns: The share price has strengthened by about 40 percent.
-
6 Months Returns: The stock has given a profit of more than 30 percent during this period.
-
2 weeks return: Even in the last two weeks, this stock has risen by about 12 percent.
The continuous rise in this stock with a face value of ₹ 10 reflects the strong business model of the company.
How is the financial health of Emcure Pharma? Know the profit figures
Amidst this reshuffle of stake, the financial results of the company also look quite strong. Company’s revenue on standalone basis in the quarter January-March 2026 (Q4FY26) ₹1,467.70 crore While during this period the company ₹233.70 crore Recorded a net profit of Rs.
If we talk about the entire financial year 2026 (FY26), the company has achieved total revenue of ₹5,243.19 crore on standalone basis and annual net profit has been ₹732.96 crore. Due to this strength on the financial front, even after the exit of Bain Capital, domestic fund houses did not waste any time in buying the stock.